KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Jazz Pharmaceuticals (JAZZ) EBITDA (2016 - 2025)

Historic EBITDA for Jazz Pharmaceuticals (JAZZ) over the last 17 years, with Q3 2025 value amounting to $57.5 million.

  • Jazz Pharmaceuticals' EBITDA fell 7789.9% to $57.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$177.9 million, marking a year-over-year decrease of 12743.9%. This contributed to the annual value of $716.6 million for FY2024, which is 2386.01% up from last year.
  • Per Jazz Pharmaceuticals' latest filing, its EBITDA stood at $57.5 million for Q3 2025, which was down 7789.9% from -$686.4 million recorded in Q2 2025.
  • In the past 5 years, Jazz Pharmaceuticals' EBITDA registered a high of $260.2 million during Q3 2024, and its lowest value of -$686.4 million during Q2 2025.
  • Its 5-year average for EBITDA is $42.8 million, with a median of $86.5 million in 2022.
  • In the last 5 years, Jazz Pharmaceuticals' EBITDA crashed by 63338.6% in 2022 and then skyrocketed by 59616.77% in 2023.
  • Over the past 5 years, Jazz Pharmaceuticals' EBITDA (Quarter) stood at $49.4 million in 2021, then crashed by 633.39% to -$263.4 million in 2022, then skyrocketed by 146.51% to $122.5 million in 2023, then surged by 55.73% to $190.8 million in 2024, then tumbled by 69.85% to $57.5 million in 2025.
  • Its EBITDA was $57.5 million in Q3 2025, compared to -$686.4 million in Q2 2025 and $190.8 million in Q4 2024.